The use of genomics and proteomics for the recognition of transplantation rejection of solid organs

Recent Patents on DNA and Gene Sequences

Volumn 3, Issue 1, 2009, Pages 1-6

  Fiorinia, Ryan N ^a   Nicoud, Ian B ^b   Fiorini, Jennifer H ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BioLife Solutions Inc   (United States)

^c Coastal Carolina Surgical Specialists ^*  (United States)

Author keywords

Autoimmune disease; Detecting solid organ rejection; DNA sequence; Genetic mapping; Genomics and proteomics; Transplant rejection; Transplantation of solid organs

Indexed keywords

INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRAFT REJECTION; BIOCHIP; BIOPSY; BLOOD CLOTTING; CELLULAR IMMUNITY; CHEMOTAXIS; CHRONIC GRAFT REJECTION; CYTOTOXICITY; GENE EXPRESSION; GENE MAPPING; GENETIC VARIABILITY; GENOMICS; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; UPREGULATION; GENETICS; LEGAL ASPECT; METABOLISM; METHODOLOGY; PATENT; PHYSIOLOGY;

GENOMICS; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; PATENTS AS TOPIC; PROTEOMICS;

EID: 60549088103     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221509787236165     Document Type: Review

References (45)

1. Gwinner W. Renal transplant rejection markers. World J Urol 2007; 25(5): 445-455.
2. Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR. Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int Immunopharmacol 2007; 7(14): 1948-1960.
3. Valente M, Furian L, Marino SM, et al. Histological markers of humoral rejection in renal transplant patients. Transplant Proc 2007; 39(6): 1827-1829.
4. Ardoin SP, Pisetsky DS. The role of cell death in the pathogenesis of autoimmune disease: Hmgb1 and microparticles as intercellular mediators of inflammation. Mod Rheumatol 2008.
5. Bodolay E, Derfalvi B, Gergely P, Poor G. [when does an autoimmune disease begin? Importance of the early diagnosis]. Orv Hetil 2007; 148: 25-30.
6. Beris P, Miescher PA. Current drug therapy of autoimmune diseases. Press Med 1983; 12(41): 2587-2591.
7. Montano LAJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007; 4(4): 202-214.
8. Zeniya M, Toda G. Autoimmune liver disease: Current therapy. Intern Med 2000; 39(4): 346-347.
9. Takahashi H. Current topics relating to autoimmune hepatitis diagnosis and therapy. Hepatol Res 2007; 37 Suppl 3: S510-514.
10. Vostrikov GP. Current treatment of autoimmune diseases: Anticytokine therapy. Eksp Klin Gastroenterol 2003(2): 50-51.
11. Thummel KE. A genetic test for immunosuppressant dose selection. Pharmacogenetics 2004; 14(3): 145-146.
12. Yatscoff RW, Keenan R, LeGatt DF. Single-dose pharmacokinetics of the new immunosuppressant rs-61443 in the rabbit. Ther Drug Monit 1993; 15(5): 400-404.
13. Matinlauri IH, Nurminen MM, Hockerstedt KA, Isoniemi HM. Changes in liver graft rejections over time. Transplant Proc 2006; 38(8): 2663-2666.
14. Kawagishi N, Takeda I, Miyagi S, et al. Management of antiallogeneic antibody elimination by apheresis in living donor liver transplantation. Ther Apher Dial 2007; 11(5): 319-324.
15. Figueiredo C, Horn PA, Blasczyk R, Seltsam A. Regulating mhc expression for cellular therapeutics. Transfusion 2007; 47(1): 18-27.
16. Dengler TJ, Gleissner CA, Klingenberg R, Sack FU, Schnabel PA, Katus HA. Biomarkers after heart transplantation: nongenomic Heart Fail Clin 2007; 3(1): 69-81.
17. Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999; 60(9): 826-832.
18. Pacheco-Silva A. Immune function, as assessed by the immuknow assay, correlates with clinical outcomes in transplant recipients. Nat Clin Pract Nephrol 2007; 3(4): 196-197.
19. Hooper E, Hawkins DM, Kowalski RJ, et al. Establishing pediatric immune response zones using the cylex immuknow assay. Clin Transplant 2005; 19(6): 834-839.
20. Yamani MH, Taylor DO, Rodriguez ER, et al. Transplant vasculopathy is associated with increased allomap gene expression score. J Heart Lung Transplant 2007; 26(4): 403-406.
21. Israeli M, Yussim A, Mor E, Sredni B, Klein T. Preceeding the rejection: In search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol 2007; 18(1): 7-12.
22. Wohlgemuth, J., Fry, K., Woodward, R., Ly, N., Prentice, J.: US20037235358 (2003).
23. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003; 5(6): 279-287.
24. Cappellesso S, Valentin JF, Giraudeau B, et al. Association of donor tnfrsf6 (fas) gene polymorphism with acute rejection in renal transplant patients: A case-control study. Nephrol Dial Transplant 2004; 19(2): 439-443.
25. Lande JD, Patil J, Li N, Berryman TR, King RA, Hertz MI. Novel insights into lung transplant rejection by microarray analysis. Proc Am Thorac Soc 2007; 4(1): 44-51.
26. Wisniewski A, Kusztal M, Magott-Procelewska M, et al. Possible association of cytotoxic t-lymphocyte antigen 4 gene promoter single nucleotide polymorphism with acute rejection of allogeneic kidney transplant. Transplant Proc 2006; 38(1): 56-58.
27. Allanach K, Mengel M, Einecke G, et al. Comparing microarray versus rt-pcr assessment of renal allograft biopsies: Similar performance despite different dynamic ranges. Am J Transplant 2008; 8(5): 1006-1015.
28. Wohlgemuth, J., Tayama, D., Walther, D., Preeti, L.: WO2006029184 ( 2006).
29. Strom, T.: US20070082356 (2007).
30. Kienle, S., Joubert, R.: EP000253514 (2007).
31. Rose, M., Dunn, M.: EP000953220 (2001).
32. Borozdenkova S, Westbrook JA, Patel V, et al. Use of proteomics to discover novel markers of cardiac allograft rejection. J Proteome Res 2004; 3(2): 282-288.
33. Klatzmann, D., Lemoine, F.: US2004000584728 (2004).
34. VanNeerven, R., Jules, J.: WO2005077980 (2005).
35. Fiorini RN, Shafizadeh SF, Polito C, et al. Anti-endotoxin monoclonal antibodies are protective against hepatic ischemia/ reperfusion injury in steatotic mice. Am J Transplant 2004; 4(10): 1567-1573.
36. McAllister, G., Gorski, R., Bienkowska, J.: US2004000557234 (2004).
37. Shankarkumar U, Ghosh K. Mhc non -HLA gene polymorphisms in transplantation. Indian J Pathol Microbiol 2007; 50(4): 881-885.
38. VandenBerg J, Hepkema B, Geertsma A, et al. Long-term outcome of lung transplantation is predicted by the number of hla-dr mismatches. Transplantation 2001; 71(3): 368-373.
39. Tuse, D.: WO02075306A1 (2002).
40. Polack, F., Irusta, P., Kleeberger, S.: US2006000641625 (2006).
41. Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data. Transplantation 2007; 83(5): 582-587.
42. Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004; 8(3): 267-272.
43. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2001; 181(5): 475-479.
44. Binet I, Nickeleit V, Hirsch HH, et al. Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 1999; 67(6): 918-922.
45. Kaye, J.: US20050152893 (2005).